Mahsa Mottaghizadeh-Jazi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mahsa Mottaghizadeh-Jazi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Khanahmad
Student Research Committee, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
2 shared publications - Alireza Farsinejad
Department of Hematology and Laboratory Sciences, Faculty of Allied Medical Sciences, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication - Amin Sadeghi Dousari
Stem Cells and Regenerative Medicine Innovation Center, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication - Azadeh Rezazadeh
Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
1 shared publication - Faeze Mazloom
Department of Hematology and Medical Laboratory Sciences Kerman University of Medical Sciences Kerman Iran
1 shared publication - Maryam Shayanmanesh
Departments of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 20 April 2026
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 70 (8) , e70421
Probiotics in the Management of Chemotherapy‐Induced Gastrointestinal Complications: Underlying Mechanisms and Potential Applications
The intestinal microbial population safeguards the gut's health through dynamic interactions with adjacent epithelial and immune cells. Therefore, microbial imbalance in the gastrointestinal (GI) tract may lead to impaired immune system function, disrupted epithelial integrity, and elevated susceptibility to systemic health issues. Chemotherapy, a nonspecific, widely used therapeutic option in cancer treatment, can harm rapidly proliferating intestinal epithelial cells and disrupt intestinal microbial balance, leading to chemotherapy‐induced GI adverse events, including mucositis, diarrhea, constipation, bowel inflammation, nausea, vomiting, flatulence, dyspepsia, gastritis, stomatitis, and abdominal pain and distention. These adverse events significantly impair the quality of life of cancer patients. Clinical evidences show promising efficacy for probiotics, especially Lactobacillus spp. and Bifidobacterium spp., in restoring gut microbiota diversity, enhancing mucosal integrity, and modulating inflammatory cytokines (e.g., IL‐10, IL‐6, and TNF‐a). However, study design variabilities, strain‐specific effects, and safety concerns in immunocompromised cases remain challenging. This review explores the underlying mechanisms of preventing chemotherapy‐induced GI complications using probiotics. Understanding these mechanisms can facilitate probiotic integration into supportive oncology care protocols. This review also highlights the need for standard protocols, personalized therapies, and advanced multi‐omics approaches to discover the host–microbe interactions.
- 20 April 2026
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 70 (8) , e70421
Probiotics in the Management of Chemotherapy‐Induced Gastrointestinal Complications: Underlying Mechanisms and Potential Applications
The intestinal microbial population safeguards the gut's health through dynamic interactions with adjacent epithelial and immune cells. Therefore, microbial imbalance in the gastrointestinal (GI) tract may lead to impaired immune system function, disrupted epithelial integrity, and elevated susceptibility to systemic health issues. Chemotherapy, a nonspecific, widely used therapeutic option in cancer treatment, can harm rapidly proliferating intestinal epithelial cells and disrupt intestinal microbial balance, leading to chemotherapy‐induced GI adverse events, including mucositis, diarrhea, constipation, bowel inflammation, nausea, vomiting, flatulence, dyspepsia, gastritis, stomatitis, and abdominal pain and distention. These adverse events significantly impair the quality of life of cancer patients. Clinical evidences show promising efficacy for probiotics, especially Lactobacillus spp. and Bifidobacterium spp., in restoring gut microbiota diversity, enhancing mucosal integrity, and modulating inflammatory cytokines (e.g., IL‐10, IL‐6, and TNF‐a). However, study design variabilities, strain‐specific effects, and safety concerns in immunocompromised cases remain challenging. This review explores the underlying mechanisms of preventing chemotherapy‐induced GI complications using probiotics. Understanding these mechanisms can facilitate probiotic integration into supportive oncology care protocols. This review also highlights the need for standard protocols, personalized therapies, and advanced multi‐omics approaches to discover the host–microbe interactions.
- Open Access
- 28 November 2025
- Published by Springer Nature in Thrombosis Journal
- Vol. 23 (1)
Molecular diagnosis of inherited platelet disorders: a tale of two realities – advanced vs. resource-limited setting
Inherited platelet disorders are a heterogeneous group of rare conditions characterized by impaired platelet production or function, often leading to signi
- 28 November 2025
- Published by Springer Nature in Thrombosis Journal
- Vol. 23 (1)
Open AccessMolecular diagnosis of inherited platelet disorders: a tale of two realities – advanced vs. resource-limited setting
Inherited platelet disorders are a heterogeneous group of rare conditions characterized by impaired platelet production or function, often leading to signi